Neoplasms

Digestive System Diseases

All Conditions

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Utidelone Injection: 40 mg/m2/day, IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle, administered to enrolled patients with advanced or metastatic CRC

utidelone monotherapy in patients with advanced or metastatic CRC by iv transfusing utidelone injection

utidelone injection

RUIHUA XU, MD

To assess the effectiveness and safety of utidelone injection in patients with advanced or metastatic colorectal cancer (CRC) as a phase II trial

Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer

Open, Multicenter, Monotherapy, Phase II Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer After Failure or Intolerability to Second-line Standard Treatment

Reflected by percentage of tumor size reduction or regression, assessed by imaging techniques and expressed as Objective Response Rate (ORR）ORR is defined as the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR) according to RECIST. 1.1.

PFS is defined as the duration of time from first study treatment to disease progression or death from any cause as documented by the investigator

OS is defined as the duration of time from first study treatment until death from any cause.

Observe and record adverse effects and severe adverse effects associated with utidelone injection

Chengdu Biostar Pharmaceuticals

Beijing Biostar Pharmaceuticals Co., Ltd.

Rare Diseases

Stomach Neoplasms

Liver Neoplasms

Liver Diseases

Stomach Cancer

Patients receive Metatinib orally 200mg once daily (QD) or 100mg twice daily (BID) until disease progression or unacceptable toxicity occurred.

Metatinib Tromethamine

Shuangling Deng, MS

Yanhua Ding, MD

Feng Bi, MD

This is an open-label, multicenter study designed to assess the safety, tolerability, preliminary efficacy and pharmacokinetics of Metatinib Tromethamine tablet in patients with advanced or metastatic gastric cancer, liver cancer, colorectal cancer,or con squamous NSCLC. Patients receive Metatinib orally 200mg once daily (QD) or 100mg twice daily (BID) until disease progression or unacceptable toxicity occurred. The study will determine whether MET gene mutation, amplification, as well as MET protein overexpression in tumor tissue correlate with treatment efficacy and clinical outcome. The potential PD biomarker for Metatinib will also be explored.

Study of Metatinib Tromethamine Tablet

A Phase Ib Clinical Study of the Tolerance, Safety and Preliminary Efficacy Observation of Single-/Multiple- Doses of Metatinib Tromethamine Tablets in Patients With Advanced or Metastatic Solid Tumor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer	NCT03906565	Advanced or Met...	utidelone injec...	18 Years - 70 Years	Beijing Biostar Pharmaceuticals Co., Ltd.
Study of Metatinib Tromethamine Tablet	NCT02650375	Advanced or Met... Advanced or Met... Advanced or Met... Advanced or Met...	Metatinib Trome...	18 Years - 75 Years	Jiangsu Simcere Pharmaceutical Co., Ltd.

Spots Global Cancer Trial Database for advanced or metastatic crc